Scientists Identify KRAS Weakness in Nearly Every Pancreatic Cancer Case, Where 5-Year Survival Is 13%
Updated
Updated · The Washington Post · May 24
Scientists Identify KRAS Weakness in Nearly Every Pancreatic Cancer Case, Where 5-Year Survival Is 13%
3 articles · Updated · The Washington Post · May 24
KRAS emerged as a central vulnerability in pancreatic cancer after scientists found the mutated protein drives aggressive tumor growth in nearly every case.
The finding targets a disease with a 13% five-year survival rate, underscoring why researchers have long searched for a tractable weak point.
Scientists first linked KRAS to cancer in the early 1980s, but the protein's role in pancreatic tumors later proved especially important because it fuels both growth and spread.
The discovery reframes one of the deadliest cancers as having an Achilles' heel that had been visible for decades despite its reputation as undruggable.
New drugs can double survival, but can science outsmart the tumor's inevitable resistance to treatment?
With breakthrough drugs extending life by months, is the real cure actually a simple, early detection test?
Transforming Pancreatic Cancer Care: Daraxonrasib Delivers 13.2-Month Median Survival in KRAS-Mutant Disease
Overview
Pancreatic cancer has long been one of the deadliest cancers, with most patients facing poor outcomes and limited treatment options. The disease is aggressive, often spreading quickly and leading to a five-year survival rate of just 3 percent for those with advanced cases. This grim reality has created an urgent need for better therapies. Daraxonrasib has emerged as a major breakthrough, offering new hope by precisely targeting the most common gene mutation in pancreatic cancer. Its arrival marks a significant step forward, promising improved survival and a brighter future for patients who previously had few options.